Library · Synthetic pentapeptide (growth hormone secretagogue)
Ipamorelin
A synthetic pentapeptide first described in 1998 as a selective growth-hormone secretagogue in animal studies.
This entry summarises published research. It is not guidance on use, and research-grade material is not for human or veterinary use.
What it is
Ipamorelin is a five-amino-acid synthetic peptide. The 1998 paper that characterised it in animals called it the first selective growth-hormone secretagogue: a compound that stimulates growth-hormone release without the broad hormonal effects of earlier molecules.
What has been studied
The pharmacology cited here comes from animal studies. This entry does not yet cover later clinical literature; we will add it only after checking the primary sources.
Reading supplier listings
Ipamorelin is often sold combined with CJC-1295 (no DAC) in a single vial. In that case, each component needs its own result on the certificate.
Regulatory status
Research vendors supply it as a laboratory reagent. None of the sources cited here describes it as an approved medicine, and we have not searched national registers for it. Confirm registration status with the authority in your country (see the country regulations pages).
Known limitations of the evidence
- The characterisation cited here (1998) was in animals.
- We have not reviewed later clinical literature for this entry; it will be extended once those sources are verified.
References
- Animal study Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998 (opens an external site in a new tab) link checked 4 Oct 2026
- Chemical database Ipamorelin — PubChem CID 9831659 (opens an external site in a new tab) link checked 4 Oct 2026